Search results for "CAPECITABINE"

showing 3 items of 73 documents

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-labe…

2013

Summary Background Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine-cisplatin chemotherapy in patients with advanced gastric or gastro-oesophageal junction cancer. Methods In our open-label, randomised phase 3 trial (EXPAND), we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction. We enrolled patients at 164 sites (teaching hospitals and clinics) in 25 countries, and randomly assigned eligible participants (1:1) to receive first-line chemotherapy with …

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisCetuximabbusiness.industryPopulationMedizinRashSurgeryRamucirumabCapecitabineRegimenOncologyInternal medicineClinical endpointMedicinemedicine.symptombusinesseducationmedicine.drugThe Lancet Oncology
researchProduct

“Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients: South…

2008

metastatic colorectal cancercapecitabineSettore MED/06 - Oncologia Medica
researchProduct

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a m…

2023

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recrui…

neoadjuvant treatmentCancer ResearchOncologytriple negative breast canceradjuvant capecitabineresidual tumorsresidual tumortreatment discontinuationFrontiers in Oncology
researchProduct